Neuronetics and Humana have partnered to enhance adolescent mental healthcare by expanding access to transcranial magnetic stimulation (TMS) therapy for young people suffering from major depressive disorder (MDD). Humana is the first commercial insurance provider to update its policy in response to the FDA’s recent clearance of NeuroStar TMS for adolescents aged 15-21. This policy change, affecting around 600,000 young individuals, includes a requirement for medical director review for treatment requests from those aged 15-17.
This policy update comes at a critical time, addressing the significant public health concern of adolescent depression, which impacts approximately 4.3 million adolescents in the United States. MDD can severely affect academic performance, social interactions, and overall well-being during a vital developmental stage. NeuroStar TMS therapy offers a promising non-drug, noninvasive treatment option for adolescents who have not achieved satisfactory results with traditional medications.
Keith J. Sullivan, President & CEO of Neuronetics, hailed the FDA clearance and Humana’s swift policy update as major advancements in adolescent mental health treatment. He highlighted the urgent need for effective treatment options for this often-underserved population and expressed satisfaction with the positive policy changes supporting TMS coverage. This collaboration aims to provide new hope and effective treatment for young people with depression and their families.
Click here to read the original news story.